Gili Hart

CF Foun­da­tion backs a new round for a biotech up­start out to ri­val the mighty Ver­tex

As a post­doc fel­low in 1989, Bat­she­va Kerem was part of the dogged team that worked with cur­rent NIH di­rec­tor Fran­cis Collins to iden­ti­fy the faulty gene be­hind cys­tic fi­bro­sis. Now, more than three decades lat­er, she’s lead­ing one com­pa­ny’s ef­forts to al­ter a key mu­ta­tion in that gene — and she just got $28.5 mil­lion to do it.

On Thurs­day morn­ing, Jerusalem-based SpliSense took the wraps off a Se­ries B round to bring its an­ti­sense oligonu­cleotide (ASO) ther­a­py in­to the clin­ic. The round in­cludes up to $8.4 mil­lion from the Cys­tic Fi­bro­sis Foun­da­tion, bring­ing SpliSense’s to­tal raise to just over $30 mil­lion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.